Literature DB >> 24046283

miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma.

Paige E Bennett1, Lynne Bemis, David A Norris, Yiqun G Shellman.   

Abstract

Melanoma is a very aggressive skin cancer with increasing incidence worldwide. MicroRNAs are small, noncoding RNAs that regulate gene expression of targeted gene(s). The hallmark of cancer model outlined by Hanahan and Weinberg offers a meaningful framework to consider the roles of microRNAs in melanoma development and progression. In this systematic review of the literature, we associate what is known about deregulation of microRNAs and their targeted genes in melanoma development with the hallmarks and characteristics of cancer. The diagnostic and therapeutic potential of microRNAs for future melanoma management will also be discussed.

Entities:  

Keywords:  BRAF; MITF; miR-137; miR-18b; miR-214

Mesh：

Substances：

Year:  2013        PMID： 24046283      PMCID： PMC4596730          DOI： 10.1152/physiolgenomics.00116.2013

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN： 1094-8341            Impact factor:   3.107


  91 in total

1.  New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites.

Authors:  Inhan Lee; Subramanian S Ajay; Jong In Yook; Hyun Sil Kim; Su Hyung Hong; Nam Hee Kim; Saravana M Dhanasekaran; Arul M Chinnaiyan; Brian D Athey
Journal:  Genome Res       Date:  2009-03-31       Impact factor: 9.043

Review 2.  Ras, Raf, and MAP kinase in melanoma.

Authors:  Jason F Solus; Stefan Kraft
Journal:  Adv Anat Pathol       Date:  2013-07       Impact factor: 3.875

3.  MicroRNA-340-mediated degradation of microphthalmia-associated transcription factor mRNA is inhibited by the coding region determinant-binding protein.

Authors:  Srikanta Goswami; Rohinton S Tarapore; Jessica J Teslaa; Yevgenya Grinblat; Vijayasaradhi Setaluri; Vladimir S Spiegelman
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

4.  A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth.

Authors:  K L Streicher; W Zhu; K P Lehmann; R W Georgantas; C A Morehouse; P Brohawn; R A Carrasco; Z Xiao; D A Tice; B W Higgs; L Richman; B Jallal; K Ranade; Y Yao
Journal:  Oncogene       Date:  2011-08-22       Impact factor: 9.867

5.  KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel.

Authors:  Samrat T Kundu; Sunitha Nallur; Trupti Paranjape; Marta Boeke; Joanne B Weidhaas; Frank J Slack
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

6.  KIT as a therapeutic target in metastatic melanoma.

Authors:  Richard D Carvajal; Cristina R Antonescu; Jedd D Wolchok; Paul B Chapman; Ruth-Ann Roman; Jerrold Teitcher; Katherine S Panageas; Klaus J Busam; Bartosz Chmielowski; Jose Lutzky; Anna C Pavlick; Anne Fusco; Lauren Cane; Naoko Takebe; Swapna Vemula; Nancy Bouvier; Boris C Bastian; Gary K Schwartz
Journal:  JAMA       Date:  2011-06-08       Impact factor: 56.272

Review 7.  MicroRNAs in melanoma biology.

Authors:  Manfred Kunz
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

8.  MicroRNA-dependent regulation of cKit in cutaneous melanoma.

Authors:  O Igoucheva; V Alexeev
Journal:  Biochem Biophys Res Commun       Date:  2009-01-04       Impact factor: 3.575

9.  MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression.

Authors:  M Kappelmann; S Kuphal; G Meister; L Vardimon; A-K Bosserhoff
Journal:  Oncogene       Date:  2012-07-16       Impact factor: 9.867

10.  Interferon-γ-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells.

Authors:  Martina J Schmitt; Demetra Philippidou; Susanne E Reinsbach; Christiane Margue; Anke Wienecke-Baldacchino; Dorothee Nashan; Iris Behrmann; Stephanie Kreis
Journal:  Cell Commun Signal       Date:  2012-12-17       Impact factor: 5.712
View more
  22 in total

1.  MicroRNA-15a inhibits the growth and invasiveness of malignant melanoma and directly targets on CDCA4 gene.

Authors:  Christopher Alderman; Ayoub Sehlaoui; Zhaoyang Xiao; Yixin Yang
Journal:  Tumour Biol       Date:  2016-08-04

Review 2.  A comprehensive review of the genetic and biological evidence supports a role for MicroRNA-137 in the etiology of schizophrenia.

Authors:  Kensuke Sakamoto; James J Crowley
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-06-14       Impact factor: 3.568

3.  MicroRNA-373 promotes cell migration via targeting salt-inducible kinase 1 expression in melanoma.

Authors:  Xinping Bai; Ming Yang; Yi Xu
Journal:  Exp Ther Med       Date:  2018-09-21       Impact factor: 2.447

Review 4.  BANCR: a cancer-related long non-coding RNA.

Authors:  Xin Yu; Heyi Zheng; Matthew Tv Chan; William Ka Kei Wu
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

Review 5.  Melanoma epigenetics: novel mechanisms, markers, and medicines.

Authors:  Jonathan J Lee; George F Murphy; Christine G Lian
Journal:  Lab Invest       Date:  2014-06-30       Impact factor: 5.662

6.  miR-34a inhibits melanoma growth by targeting ZEB1.

Authors:  Yazhen Xu; Bingyu Guo; Xiaoyan Liu; Kai Tao
Journal:  Aging (Albany NY)       Date:  2021-06-08       Impact factor: 5.682

7.  miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2.

Authors:  Szu-Mam Liu; Jean Lu; Hoong-Chien Lee; Feng-Hsiang Chung; Nianhan Ma
Journal:  Oncotarget       Date:  2014-10-15

Review 8.  MicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical use.

Authors:  S Patrick Nana-Sinkam; Carlo M Croce
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

Review 9.  Epigenetic regulation in human melanoma: past and future.

Authors:  Debina Sarkar; Euphemia Y Leung; Bruce C Baguley; Graeme J Finlay; Marjan E Askarian-Amiri
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

10.  MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches.

Authors:  Joseph Markowitz; Zachary Abrams; Naduparambil K Jacob; Xiaoli Zhang; John N Hassani; Nicholas Latchana; Lai Wei; Kelly E Regan; Taylor R Brooks; Sarvani R Uppati; Kala M Levine; Tanios Bekaii-Saab; Kari L Kendra; Gregory B Lesinski; J Harrison Howard; Thomas Olencki; Philip R Payne; William E Carson
Journal:  Onco Targets Ther       Date:  2016-09-29       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.